Applied Dna Scie Stock Price, News & Analysis

Applied DNA Sciences (NASDAQ:APDN) announced a 1-for-15 reverse stock split effective June 2, 2025. The company's outstanding shares will be reduced from approximately 7.8 million to 519 thousand. Trading will continue under the symbol "APDN" with a new CUSIP number (03815U607). The reverse split aims to meet Nasdaq's $1.00 minimum bid price requirement for continued listing. The split was approved by stockholders on May 22, 2025, granting the Board discretion for a ratio between 1:5 and 1:50. Proportional adjustments will be made to stock options, restricted stock units, and warrants. No fractional shares will be issued, and the $0.001 par value remains unchanged.

Applied DNA Sciences (NASDAQ:APDN) reported Q2 FY2025 financial results with total revenues of $983K, up 6% year-over-year. The company's LineaRx segment, focused on therapeutic DNA production, saw a 44% revenue increase, while MDx Testing Services revenue declined 33%. The company reported a net loss of $3.3M, improved from $4.5M loss in Q2 FY2024, and held cash and equivalents of $6.8M. Following strategic restructuring, Applied DNA expects quarterly cash burn to decrease starting Q3 FY2025. The company's GMP Site 1 facility, operational since January, can support annual revenue of $10-30M. Notable developments include new customer acquisitions, follow-on orders, and planned launch of LineaPCR™ in Q4'25. The company positions LineaRx as North America's largest PCR-based producer of cell-free DNA, focusing on meeting biopharma's enzymatic DNA demand.

Applied DNA Sciences (NASDAQ:APDN) has announced it will release its Q2 FY2025 financial results on May 15, 2025, after U.S. market close. The company will file its Form 10-Q concurrently. Following its Annual Meeting of Stockholders on May 22, Applied DNA will host an intra-quarter investor update call on June 3, 2025, at 4:30 p.m. ET, where management will discuss strategic priorities.

The conference call will be accessible via multiple channels, including domestic (844-887-9402), international (412-317-6798), and Canadian (866-605-3852) dial-in numbers. A webcast replay will be available for 7 days following the call, with access codes provided for different regions.

Applied DNA Sciences' (NASDAQ:APDN) subsidiary LineaRx has completed its transition to a U.S.-based supply chain for critical input materials used in its LineaDNA™ and LineaIVT™ platforms. This strategic move, responding to the 2024 BIOSECURE Act and customer demand, positions the company to support the reshoring of biopharmaceutical manufacturing operations in the United States.

As the largest PCR-based cell-free DNA producer in the U.S., LineaRx now sources over 75% of its manufacturing cost components domestically, including DNA template materials and manufacturing enzymes. The company's proprietary PCR-based platform enables rapid production of high-fidelity, cell-free DNA in quantities from milligram to multi-gram scale for genetic medicines development.

Applied DNA Sciences (NASDAQ:APDN) has successfully regained compliance with Nasdaq's minimum bid price requirement. The company, which specializes in PCR-based DNA technologies, received confirmation from Nasdaq's Listing Qualifications Department on April 7, 2025.

The company had previously fallen out of compliance on November 12, 2024, when it failed to maintain the required minimum bid price of $1.00 over 30 consecutive business days. To rectify this situation, APDN needed to maintain a closing bid price of at least $1.00 for a minimum of 10 consecutive business days.

The company exceeded this requirement by maintaining the minimum bid price for 16 consecutive business days, from March 14 through April 4, 2025. With this achievement, Nasdaq has confirmed the matter is now closed.

Applied DNA Sciences (NASDAQ:APDN) is repositioning its TR8™ PGx pharmacogenomics testing service to focus on specific use cases, starting with pre-emptive testing for DPYD gene variants. This initiative follows an FDA safety announcement regarding patients with DPYD genetic variants who may experience severe toxicities when taking fluoropyrimidine-based cancer drugs.

The company's TR8 PGx test, approved by the New York State Department of Health, can identify individuals with DPYD genotypes affecting DPD enzyme activity, important for metabolizing drugs like capecitabine and fluorouracil (5-FU). These medications, with approximately 924,000 prescriptions in 2022, are commonly used in treating various cancers including colorectal, breast, and cervical.

Statistics show that about 1 in 1,000 patients carry two DPYD gene variants causing DPD enzyme absence, while 3-8% of the population has one variant resulting in lower enzyme levels, with higher frequency in African Americans.

Applied DNA Sciences (NASDAQ:APDN) has submitted a validation package to the New York State Department of Health for approval of its laboratory-developed test (LDT) for detecting H5 bird flu. The company's Linea™ Avian Influenza H5 Dx assay (AIH5 Dx) is designed to detect and differentiate between pan-influenza A and H5 bird flu.

The development was initiated in January 2025 following increased concerns about H5 bird flu spread in dairy cows and poultry, along with human infections in U.S. workers. If approved, Applied DNA Clinical Labs (ADCL) will launch a testing service accepting samples from states recognizing New York's CLEP/CLIA certification.

The testing would be conducted at ADCL, an NYSDOH CLEP-permitted, CLIA-certified laboratory, adding to its existing diagnostic testing menu that includes mpox, SARS-CoV-2, and pharmacogenetic testing. The timeline for NYSDOH's review and potential approval remains uncertain.

Applied DNA Sciences (NASDAQ:APDN) has announced a 1-for-50 reverse stock split effective March 14, 2025. The split will reduce outstanding shares from approximately 55.2 million to 1.1 million, while maintaining trading on the Nasdaq Capital Market under the same symbol 'APDN'.

The reverse split follows stockholder approval granted on September 30, 2024, authorizing the Board to implement a split ratio between 1-for-5 and 1-for-50. The Board approved the maximum ratio on March 3, 2025, aiming to comply with Nasdaq's $1.00 minimum bid price requirement for continued listing.

The company will adjust proportionally all outstanding stock options, restricted stock units, and warrants. Fractional shares will be rounded up to the nearest whole share, and the $0.001 par value per share will remain unchanged.

Applied DNA Sciences (NASDAQ:APDN) reported Q1 fiscal 2025 financial results, announcing strategic restructuring initiatives. The company is exiting its DNA Tagging and Security Products business segment and implemented a 20% workforce reduction in January, expected to reduce annual payroll costs by 13% with one-time separation costs of $300,000.

Key financial highlights include revenue of $1.2 million (up 34% YoY), operating loss of $3.0 million, and net loss of $2.7 million. Cash position stands at $9.3 million as of December 31, 2024.

The company completed its GMP Site 1 facility in Stony Brook, NY, with an initial manufacturing capacity of approximately ten grams per annum, supporting potential annual revenues of $10-30 million. The facility received commercial operation certification in January 2025 and enables enzymatic manufacture of Linea DNA™ IVT templates for mRNA clinical trial materials.